ライフサイエンスコーパス: grave

1 " manufacturing and the product end-of-life "grave").

2 found in a localized form, the prognosis is grave.

3 locally advanced and metastatic melanoma is grave.

4 and alkalinizing disturbances, many of them grave.

5 before being deposited in a commingled mass grave.

6 se of flowers in the Shanidar IV Neanderthal grave.

7 known for such preparation and decoration of graves.

8 used by antibiotic-resistant bacteria pose a grave and growing threat to public health.

9 nterpersonal Support Evaluation List-12, the Graven and Grant Social Network Survey, the Social Probl

10 Microsomes from normal, Graves', and TSH-stimulated thyroids contained low Km D2

11 ortem intervals (PMIs), locating clandestine graves, and obtaining soil and skin trace evidence.

12 d flower linings were found in four Natufian graves at the burial site of Raqefet Cave, Mt. Carmel, I

13 rparts ranging from 39 to 86% on a cradle-to-grave basis.

14 developed and incorporated into a cradle-to-grave boundary with a functional unit of 1 MJ of combust

15 Cognitive aspects of aging represent a grave challenge for our societal circumstances as member

16 Central nervous system tumors carry grave clinical prognoses due to limited effectiveness of

17 eletal osteosarcoma (OS) has been considered grave compared with that for patients with relapse limit

18 proposed to play a role in liver fibrosis, a grave complication of biliary atresia (BA).

19 To reduce the probability of such a grave complication, preventive and precautionary measure

20 rds non-combatants on the battlefield are of grave concern in war.

21 n providing relief from this type of pain, a grave concern to the surgeons treating these soldiers.

22 ferences in innate drug resistance may be of grave consequences for disease management.

23 mall bowel, resulting, however, partially in grave consequences such as anemia.

24 se, either acute or chronic, has potentially grave consequences which include changes affecting the p

25 rough the cycle could result in defects with grave consequences.

26 mmon in critical illness and associated with grave consequences.

27 -long immunosuppression that can itself have grave consequences.

28 One grave difficulty is that even under well controlled cond

29 TSH receptor antibody-ELISA used to diagnose Graves disease ("third-generation assay") and also detec

30 man tropomodulin and a 64-kDa autoantigen in Graves disease (1D) are related: tropomodulin has 42 and

31 oimmune thyroid diseases (AITDs), comprising Graves disease (GD) and Hashimoto thyroiditis (HT), deve

32 eases (AITDs) include two related disorders, Graves disease (GD) and Hashimoto thyroiditis, in which

33 The major AITDs include Graves disease (GD) and Hashimoto's thyroiditis (HT); al

34 Graves disease (GD) is a common autoimmune thyroid disor

35 Graves disease (GD) is an autoimmune condition caused by

36 tibody generation in the autoimmune disorder Graves disease (GD).

37 s a common and debilitating manifestation of Graves disease (GD).

38 cosis (OR = 0.76, p = 1.5 x 10(-3)), but not Graves disease (OR = 1.03, p = 0.82).

39 tions causing endocrine dysfunctions such as Graves disease and hypo- and hyperthyroidism.

40 elopment of specific ligands useful to treat Graves disease and other dysfunctions of GPHRs.

41 ely 3% of women and 0.5% of men will develop Graves disease during their lifetime.

42 immune response to the TSHR, thereby causing Graves disease in genetically susceptible individuals.

43 Management of Graves disease includes treatment with antithyroid drugs

44 Graves disease is an autoimmune disorder that affects th

45 Graves disease is directly caused by thyroid-stimulating

46 The etiology of Graves disease is multifactorial, with nongenetic factor

47 Graves disease is the most common cause of persistent hy

48 Patients with Graves disease may be treated with antithyroid drugs, ra

49 are the primary therapy, but some women with Graves disease opt to receive definitive therapy with RA

50 imulating TSHR autoantibodies (TSHR-Ab's) in Graves disease patients may provide a functional explana

51 se a new adenovirus-mediated animal model of Graves disease to show that goiter and hyperthyroidism o

52 Treating Graves disease with RAI and surgery result in gland dest

53 unction (10 cases of hypothyroidism and 1 of Graves disease) developed in 11 of 19 (57.9%) of the DS

54 ne thyroid disease (Hashimoto thyroiditis or Graves disease), juvenile RA, inflammatory bowel disease

55 ue in both normal patients and patients with Graves disease), together with the humoral factors prese

56 otoxicosis Therapy Follow-up Study; 91 % had Graves disease, 79% were female, and 65% were treated wi

57 Graves disease, a common organ-specific autoimmune disea

58 patients who have a history of treatment of Graves disease, a subgroup that is not a target of scree

59 ave relevance to the pathogenesis of orbital Graves disease, an inflammatory autoimmune condition tha

60 uding type 1 diabetes, rheumatoid arthritis, Graves disease, and systemic lupus erythematosus, are as

61 fibroblasts orchestrate tissue remodeling in Graves disease, at least in part, because they exhibit e

62 actors present in the serum of patients with Graves disease, forms the basis for the immunologic atta

63 s mellitus, psoriasis, rheumatoid arthritis, Graves disease, Hashimoto thyroiditis, Crohn disease, ul

64 ssues (thyroiditis, n = 3; psoriasis, n = 2; Graves disease, n 1; membranous glomerulonephritis, n =

65 to localized overproduction of hyaluronan in Graves disease.

66 an, hyaluronan, which accumulates in orbital Graves disease.

67 lating variety are the cause of hyperthyroid Graves disease.

68 and provide new insight into the etiology of Graves disease.

69 e receptor (TSHR), is the primary antigen of Graves disease.

70 The most frequent cause is Graves' disease (autoimmune hyperthyroidism).

71 Autoimmune thyroid disease (AITD), including Graves' disease (GD) and Hashimoto's thyroiditis (HT), i

72 eported recently that IgG from patients with Graves' disease (GD) can induce the expression of the CD

73 II-encoded HLA-DRB1-DQA1-DQB1 haplotype with Graves' disease (GD) has been known for several years.

74 Graves' disease (GD) is a common autoimmune disease (AID

75 Graves' disease (GD) is a common thyroid disease, and Gr

76 Graves' disease (GD) is an autoimmune process involving

77 Graves' disease (GD) is an autoimmune thyroid disease de

78 Graves' disease (GD) is an autoimmune thyroid disorder t

79 Graves' disease (GD) is associated with T cell infiltrat

80 Graves' disease (GD), an autoimmune process involving th

81 rbital fibroblasts (GOFB) from patients with Graves' disease (GD), as well as fibrocyte abundance, we

82 In autoimmune Graves' disease (GD), autoantibodies bind to the thyrotr

83 n's disease, and thyroid follicular cells in Graves' disease (GD).

84 athy are connective tissue manifestations of Graves' disease (GD).

85 thyroid function and is targeted by IgGs in Graves' disease (GD-IgG).

86 tis are more common than hyperthyroidism and Graves' disease (strong evidence).

87 This single autoantigenic target makes Graves' disease a prime candidate for Ag-specific immuno

88 In Graves' disease a specific combination of polymorphisms

89 les are more distal than those identified in Graves' disease and are in LD with Graves' disease prote

90 The autoimmune thyroid diseases (AITD), Graves' disease and chronic lymphocytic thyroiditis (CLT

91 the common causes of thyrotoxicosis, such as Graves' disease and functioning nodular goiters, there a

92 ld of autoimmune thyroiditis (represented by Graves' disease and Hashimoto's thyroiditis) since Janua

93 genes is homologous to a gene implicated in Graves' disease and it, ANT2 and two others are confirme

94 ificant difference in the ADC values between Graves' disease and painless thyroiditis (P=0.001).

95 ighted MR imaging in differentiation between Graves' disease and painless thyroiditis.

96 hat manifest during the acute phase, such as Graves' disease and systemic lupus erythematosus, are di

97 New therapeutic modalities for both Graves' disease and the associated orbitopathy have hast

98 Because of the low remission rate in Graves' disease and the inability to cure toxic nodular

99 e link between the orbital manifestations of Graves' disease and those in the pretibial skin, localiz

100 thogenic TSHR Abs as detected using clinical Graves' disease assays.

101 is produces a novel truncated version of the Graves' disease carrier protein-like protein that lacks

102 ode a protein with homology to the mammalian Graves' disease carrier proteins.

103 (in total 42 agranulocytosis cases and 1,208 Graves' disease controls), using direct human leukocyte

104 e the preferred therapy for the treatment of Graves' disease during pregnancy.

105 e thyroid gland can be used to differentiate Graves' disease from painless thyroiditis in patients wi

106 sed as a threshold value for differentiating Graves' disease from painless thyroiditis, the best resu

107 ance pathogenic Ab production and exacerbate Graves' disease in humans.

108 Ag-specific immunotherapies aimed at curing Graves' disease in humans.

109 une disease, autoimmune thyroid disease (and Graves' disease in particular) contributes disproportion

110 Treatment options for Graves' disease include antithyroid drugs, radioactive i

111 Graves' disease is an autoimmune disorder that causes hy

112 The classic clinical triad of Graves' disease is hyperthyroidism, diffuse goiter, and

113 Graves' disease is the leading cause of hyperthyroidism

114 serve this association in the organ-specific Graves' disease or Addison's disease.

115 at least 1 member who had both SLE and AITD (Graves' disease or Hashimoto thyroiditis).

116 revious thyroid disease, particularly either Graves' disease or Hashimoto thyroiditis, suggesting the

117 umber in cohorts of patients with autoimmune Graves' disease or hepatitis B infection, whereas G138G

118 ulation iodine intake do not affect risk for Graves' disease or thyroid cancer, but correction of iod

119 Similarly, the majority of Graves' disease patients develop improved function over

120 eactivity in sera from 45 Hashimoto's and 47 Graves' disease patients.

121 tified in Graves' disease and are in LD with Graves' disease protective alleles identified in both of

122 other patients with thyroiditis and two with Graves' disease recognized only the whole 589-633 fragme

123 Graves' Disease results from the production of autoantib

124 Graves' disease results from thyroid-stimulating Abs (TS

125 ither of the 2 SNPs recently associated with Graves' disease showed evidence for association in the u

126 The mean ADC value of the thyroid gland in Graves' disease was 2.03+/-0.28x10(-3) mm(2)/sec, and in

127 ween induced and spontaneous mouse models of Graves' disease with implications for potential immunoth

128 In 3 of the 14 regions, TCF7L2 (T2D), CTLA4 (Graves' disease) and CDKN2A-CDKN2B (T2D), much of the po

129 schizophrenia risk (rheumatoid arthritis and Graves' disease), and DICER1 is pivotal in miRNA process

130 thyroiditis) and autoimmune thyrotoxicosis (Graves' disease).

131 ion has been found in the thyroid condition, Graves' disease, as well as in mothers of homosexual men

132 s of risk of the common autoimmune disorders Graves' disease, autoimmune hypothyroidism and type 1 di

133 cells to human serum from two patients with Graves' disease, but not control sera, led to secretion

134 The most common cause of this syndrome is Graves' disease, followed by toxic multinodular goitre,

135 The most common cause of hyperthyroidism is Graves' disease, followed by toxic nodular goitre.

136 e 1 diabetes mellitus, rheumatoid arthritis, Graves' disease, Hashimoto thyroiditis, autoimmune thyro

137 ta, ankylosing spondylitis, dermatomyositis, Graves' disease, Hashimoto thyroiditis, insulin-dependen

138 f Trp(620) with another autoimmune disorder, Graves' disease, in 1,734 case and control subjects (P =

139 mulating autoantibodies (TSAb), the cause of Graves' disease, interact with this region of the TSHR i

140 halmopathy (TAO), an autoimmune component of Graves' disease, is associated with profound connective

141 in receptor (TSHR), the major autoantigen in Graves' disease, is posttranslationally modified by intr

142 rst identified as a potential autoantigen in Graves' disease, is similar to the tropomodulin (Tmod) f

143 ically to treat autoimmune diseases, such as Graves' disease, may also diminish pathological inflamma

144 t from PGP, predictions of Gilbert syndrome, Graves' disease, non-Hodgkin lymphoma, and various blood

145 Propylthiouracil (PTU), used to treat Graves' disease, occasionally induces a lupus-like syndr

146 opathy, a condition commonly associated with Graves' disease, remains inadequately treated.

147 his gene with type 1 diabetes mellitus (DM), Graves' disease, rheumatoid arthritis (RA), and multiple

148 In Graves' disease, the orbit of the eye can become severel

149 in thyroidal T3 production in patients with Graves' disease, toxic adenomas, and, perhaps, iodine de

150 sues involved in Hashimoto's thyroiditis and Graves' disease, we performed ex vivo analysis of lympho

151 chanistic framework for molecular mimicry in Graves' disease, where early precursor B cells are expan

152 Graves' disease, which is autoimmune in nature, is the u

153 from a single experimental mouse undergoing Graves' disease, which shared the same H and L chain ger

154 tes (T2D), coronary artery disease (CAD) and Graves' disease.

155 manifestation most commonly associated with Graves' disease.

156 diseases, including rheumatoid arthritis and Graves' disease.

157 r immune responses localized to the orbit in Graves' disease.

158 contributing to the relative T3 toxicosis of Graves' disease.

159 iated with both type 1 diabetes mellitus and Graves' disease.

160 roduced from lymphocytes from a patient with Graves' disease.

161 tions for new studies on the pathogenesis of Graves' disease.

162 exon 33 SNP, giving an odds ratio of 6.1 for Graves' disease.

163 with HLA-DR3 in conferring susceptibility to Graves' disease.

164 loci for schizophrenia, type 1 diabetes, and Graves' disease.

165 of molecular mimicry in the pathogenesis of Graves' disease.

166 understanding the molecular pathogenesis of Graves' disease.

167 ic lymphocytic (Hashimoto's) thyroiditis and Graves' disease.

168 iagnosis, pathogenesis, and immunotherapy of Graves' disease.

169 ion and the hyperthyroidism was secondary to Graves' disease.

170 patient (C.L.A.), who also presented with a grave dysexecutive syndrome but no socially aberrant beh

171 des a single-atom modification that can have grave effects on the chemical and medicinal properties o

172 fe cycle assessment (LCA) measures cradle-to-grave environmental impacts of a product.

173 lly available immunomodulatory therapies for Graves eye disease.

174 Grave faults in design and conduct of clinical trials ha

175 very common psychotic illnesses can carry a grave functional prognosis from the initial episode and

176 body orientation, treatment, and associated grave goods within a single feature and evidence for res

177 The human remains, grave goods, and associated fauna provide rare direct da

178 t feature with associated organic and lithic grave goods, including the earliest known North American

179 In an important study of Graves hyperthyroidism, treatment with radioactive iodin

180 A prolonged course leads to remission of Graves' hyperthyroidism in about a third of cases.

181 Because Graves' hyperthyroidism is preferentially induced in BAL

182 unoglobulin G purified from 38 patients with Graves' hyperthyroidism with AF (n=17) or sinus rhythm (

183 Graves' hyperthyroidism, a common autoimmune disease cau

184 When present in patients with Graves' hyperthyroidism, AAbeta1AR and AAM2R facilitate

185 he thyrotropin receptor (TSHR), the cause of Graves' hyperthyroidism, only develop in humans.

186 thy (GO) affects 50% to 60% of patients with Graves' hyperthyroidism, resulting in exophthalmos, peri

187 py, and is the preferred choice for relapsed Graves' hyperthyroidism.

188 copresence would facilitate AF in autoimmune Graves' hyperthyroidism.

189 n the genesis of atrial fibrillation (AF) in Graves' hyperthyroidism.

190 e of paediatric diarrhoea, with particularly grave impact on infants and immunocompromised individual

191 eart failure (HF) is a systemic illness with grave implications for bodily functions.

192 The results have grave implications for the vision research community who

193 Large identified plant impressions in the graves include stems of sage and other Lamiaceae (Labiat

194 e prognosis, and 17% were considered poor or grave, indicating that they were not expected to survive

195 ce of CNT-FEDs, a screening-level, cradle-to-grave life cycle assessment (LCA) was conducted based on

196 Here a cradle-to-grave life cycle assessment from nanoparticle synthesis

197 cycle studies are used to inform a cradle-to-grave life cycle impact assessment.

198 rt on uniquely preserved 13,700-11,700-y-old grave linings made of flowers, suggesting that such use

199 e floor chiseling to accommodate the desired grave location and depth is also evident at the site.

200 The cradle-to-grave model includes two sources of CO2: natural domes a

201 Despite the grave nature of these maladies, our understanding of the

202 There is a grave need for safer antiplatelet therapeutics to preven

203 rdiovascular abnormalities, often leading to grave neurological and behavioral consequences.

204 Alternative etiologies of CN VI palsy with grave neurological implications often cannot be excluded

205 overed, paired and differentiated meteorites Graves Nunatak (GRA) 06128 and GRA 06129.

206 and the largest organic component of the CR2 Grave Nunataks (GRA) 95229 meteorite and found it to be

207 insurrection of 1916 and buried in a shallow grave on Cork prison's grounds.

208 Graves ophthalmopathy (GO) is an autoimmune disease that

209 The surgical management of Graves ophthalmopathy includes treatment of globe malpos

210 was a retrospective review of patients with Graves ophthalmopathy undergoing lower eyelid retraction

211 isease (GD) is a common thyroid disease, and Graves ophthalmopathy(GO) is the most common extra-thyro

212 the basis for the immunologic attack seen in Graves ophthalmopathy.

213 leading to the clinical findings typical of Graves ophthalmopathy.

214 ent of lower lid retraction in patients with Graves ophthalmopathy.

215 Graves' ophthalmopathy (GO) affects 50% to 60% of patien

216 Appearances of and increases in Graves' ophthalmopathy (GO) have been reported after tre

217 y a role in the etiology and pathobiology of Graves' ophthalmopathy and/or other ocular myopathies.

218 for those undergoing the orbital changes of Graves' ophthalmopathy is often challenging, even as our

219 The Graves' Ophthalmopathy Quality of Life (GO-QOL) scale wa

220 fic situations, for example, Duane syndrome, Graves' ophthalmopathy, may be particularly problematic.

221 ve involvement of the extraocular muscles in Graves' ophthalmopathy, the absence of N-CAM expression

222 lasts or fat accumulation, such as occurs in Graves' ophthalmopathy, tissue fibrosis, abnormal wound

223 Clinical Activity Score, and results on the Graves' ophthalmopathy-specific quality-of-life question

224 to the intense inflammation associated with Graves' ophthalmopathy.

225 The presence of bifoveal fusion and/or Graves orbitopathy were risk factors for these adverse o

226 ment of dysthyroid optic neuropathy (DON) in Graves' orbitopathy (GO).

227 nal failure in patients with HCV portended a grave outcome.

228 at the maternal-fetal interface, often with grave outcomes to the developing fetus (i.e., Zika virus

229 A total of 32 Graves patients and 37 eyelids underwent lower eyelid re

230 D2 mRNA was especially high in thyroids from Graves' patients and in follicular adenomas.

231 pared between groups, the mean values of the Graves' patients differed from control at all angles (F

232 First, that activated T lymphocytes from Graves' patients drive the differentiation of PPAR-gamma

233 e TSHR on the functional response to TSAb in Graves' patients' sera.

234 fficiently and neutralized autoantibodies in Graves' patients' sera.

235 bohydrate that neutralizes autoantibodies in Graves' patients' sera.

236 Together, these findings give a cradle-to-grave picture of internal waves on a basin scale, which

237 Thus, grave preparation was a sophisticated planned process, e

238 Toxicity from radiation therapy is a grave problem for cancer patients.

239 GEP80 model identified 9% of patients with a grave prognosis among those with GEP70-defined low-risk

240 s a major health care problem because of its grave prognosis and the limited effectiveness of availab

241 HIV-associated TBM carries an especially grave prognosis and there are new data describing the op

242 of 74 intensive care unit patients who had a grave prognosis and were judged to be at high risk for d

243 Despite the strikingly grave prognosis for older patients with glioblastomas, s

244 specially of chromosome 13 (CA 13), confer a grave prognosis in multiple myeloma even with tandem aut

245 LR carries a grave prognosis, especially among the elderly and those

246 systemic AL amyloidosis is associated with a grave prognosis.

247 licating acute myocardial infarction carry a grave prognosis.

248 nvolvement, which, if symptomatic, carries a grave prognosis.

249 ryptococcosis in patients with cirrhosis has grave prognosis.

250 types of lung cancers and is associated with grave prognosis.

251 s with aortic valve stenosis (AS) predicts a grave prognosis.

252 Chart documentation of "poor" or "grave" prognosis occurred "early": during induction, mai

253 esence of chromosome 13 deletion, which is a grave prognostic indicator in MM.

254 NPSLE patients, as determined by MRS, are a grave prognostic sign, indicating serious underlying his

255 ested repatriation under the Native American Graves Protection and Repatriation Act (NAGPRA).

256 ts for the differences in length between the Graves protein (572 residues) and tropomodulin (359 resi

257 ropomodulin has 42 and 41% identity with the Graves protein in the N-terminal (69 residue) and C-term

258 homologous repeats in the midsection of the Graves protein, together with the extension of a proline

259 n the cardiovascular system, many times with grave results.

260 tric and systemic comorbidities; and carry a grave risk of mortality.

261 100% of TSHR autoantibody activity in all 18 Graves' sera studied.

262 With the recently examined LBK mass grave site of Schoneck-Kilianstadten, Germany, we presen

263 Alzheimer's disease is a grave social problem in an aging population.

264 ommunity composition and structure, posing a grave threat to all amphibian populations.

265 iseases such as influenza continue to pose a grave threat to human health.

266 ne fungus Sporisorium reilianum that poses a grave threat to maize production worldwide.

267 ype 1 diabetes, rheumatoid arthritis, lupus, Graves thyroiditis, Addison disease and other autoimmune

268 ions, infectious diseases continue to take a grave toll on the population and economy of sub-Saharan

269 In patients with Graves' upper eyelid retraction, the method demonstrated

270 It was found that our patient's grave verbal generative impairment was present for tasks

271 The prognostic implications of CLN are grave, with high rates of graft failure requiring retran